NUVESSA and SOLOSEC are two branded, prescription-only options used in bacterial vaginosis care, and both have single-administration labeling. That surface similarity is where the comparison should begin—not end. Nuvessa contains metronidazole 1.3% in an intravaginal gel applicator. Solosec contains secnidazole 2 g oral granules. Their ingredients, routes, preparation steps and warnings are different, even though both are nitroimidazole antimicrobials.
A patient attracted by a one-time course should first make sure the symptoms have been evaluated as BV and not another cause of vaginitis. The clinician then weighs suitability, available evidence, medical history and the product’s labeled directions. This page does not convert one dose into the other, compare retail brands as if they were generic equivalents or imply that one provides a better result in every patient.
Read the Nuvessa product guide and the Solosec access guide for product-level identity. Our metronidazole versus secnidazole comparison covers the broader active-drug distinction without treating the two single-dose brands as the same medicine.
This comparison starts with the product, route and indication rather than a promise that one medicine is faster, stronger or cheaper. The differences in the matrix help a patient identify exactly what a clinician has prescribed for Nuvessa vs Solosec. They are not a self-treatment chart, and the actual product label should control administration.
A one-dose schedule is common to these two brands but the medicine is delivered by different routes. Nuvessa uses intravaginal metronidazole, while Solosec provides secnidazole oral granules with specific instructions for soft food. It would be inaccurate to interpret shared duration as equivalent systemic exposure, ingredient identity or interchangeability under FDA generic-drug rules.
| Comparison point | NUVESSA | SOLOSEC |
|---|---|---|
| Brand | NUVESSA | SOLOSEC |
| Ingredient | Metronidazole | Secnidazole |
| Route | Vaginal | Oral |
| Dosage form | 1.3% gel in one prefilled applicator | 2 g granules in one packet |
| Administration | Single intravaginal dose at bedtime | Single oral dose with specified soft-food instructions |
| Brand-label preparation detail | Prefilled vaginal gel; follow product instructions | Sprinkle granules onto approved soft food; consume within 30 minutes without chewing |
| Primary BV context | Single-dose intravaginal product | Single-dose oral alternative |
| BV-labeled population | Females aged 12 years and older | Females aged 12 years and older |
| Pharmacy detail | Route, 1.3%, applicator | Route, 2 g packet, preparation instructions |
| Is one a generic of the other? | No | No |
The NUVESSA applicator delivers one prefilled intravaginal gel dose at bedtime. The SOLOSEC packet instead contains 2 g oral granules; its label directs that the entire packet be sprinkled on applesauce, yogurt or pudding, consumed within 30 minutes, and swallowed without chewing or crunching the granules. They are not dissolved in water, although water may be taken afterward to aid swallowing. Those instructions identify two different prescription products, not self-treatment directions.
A single-dose label describes an administration plan, not a general statement of equivalence. The delivered active ingredient, distribution in the body and package design differ. If someone cannot use the assigned form, a clinician can reconsider the treatment plan.
The Nuvessa product label describes its BV indication and single intravaginal dose. Solosec has specific U.S. labels for BV and trichomoniasis, while CDC BV guidance discusses different recommended and alternative regimens. These sources answer related but distinct questions: what each product is approved for and how the clinical guidance positions various therapies.
Using a Solosec trichomoniasis indication to claim that Nuvessa treats trichomoniasis would be incorrect. Vaginal metronidazole gel is not the recommended trichomoniasis treatment route. The trichomoniasis treatment guide addresses that separate infection.
Both brands have U.S. BV indications in female patients aged 12 years or older, but their other labeled uses are not identical: SOLOSEC also has a trichomoniasis indication in patients aged 12 and older, whereas NUVESSA does not. A pharmacy comparison should never expand the vaginal metronidazole indication simply because secnidazole treats another infection by mouth. Clinical recommendations and FDA labeling answer different questions and should be checked separately.
An oral medicine may be preferred by some patients and a vaginal preparation by others, but the appropriate choice depends on actual contraindications and individualized factors. Allergies to nitroimidazoles, prior reactions, pregnancy or lactation circumstances and other medicines should be reviewed.
The fact that both involve one administration does not make their safety counseling identical. SOLOSEC labeling says to avoid products containing ethanol or propylene glycol during treatment and for at least two days afterward; NUVESSA has a separate label restriction covering treatment and at least 24 hours afterward. These label-specific intervals should not be copied across products. A prescriber should review relevant medicines, allergies, pregnancy and lactation circumstances before selecting either formulation.
FDA approved a 1.3% metronidazole vaginal generic that references Nuvessa in 2024. That is relevant when comparing Nuvessa with an equivalent metronidazole vaginal product. It does not make secnidazole a Nuvessa generic, and it does not confirm that a nearby pharmacy stocks either brand or generic.
If a pharmacy proposes a switch between Nuvessa and Solosec because of insurance, the active ingredient and route would change. That requires a new, clinician-approved treatment decision rather than an automatic generic dispensing process.
For Nuvessa, verify the 1.3% prefilled applicator and the vaginal route. For Solosec, verify one 2 g oral granule packet and the accompanying instructions. A bare drug name, package image or one-dose advertising claim is not sufficient identification.
Insurers may place these brand products differently on formularies. Request exact product and total-course quotes, and distinguish a prior-authorization requirement from a supply problem. This page intentionally does not assume a preferred merchant, actual price or live pharmacy stock.
Persistent or recurrent symptoms require reconsideration of the diagnosis, adherence, possible alternative infection and other clinical circumstances. Taking an extra packet or inserting another gel without authorization can result in unnecessary exposure while delaying appropriate evaluation.
Patients can help by noting the precise brand, date administered and whether the package instructions were followed. Clinicians may then decide whether to test, treat differently or arrange follow-up for recurrent BV rather than automatically repeating a single-dose medicine.
A patient who dislikes a multi-day course might prefer a one-time medicine but still need to think about whether the route is feasible. For Nuvessa, the important practical issue may be using an intravaginal prefilled applicator correctly; for Solosec, it may be taking the granule packet with the specified soft food. The two instructions cannot be combined, and a one-time schedule does not erase the need to read the package carefully.
If a patient needs a vaginal formulation, the broader vaginal metronidazole product hub provides additional context. Someone considering an oral option can review oral metronidazole forms, while recognizing that Solosec is a different active medicine from metronidazole tablets and should not be presented as one more oral metronidazole strength.
A change of route can matter to insurance and to clinical counseling. The pharmacy should explain whether the authorized product is covered and which specific package can be dispensed. If a route or drug change is proposed, the new prescription should be explicit. This protects against a seemingly simple one-dose substitution concealing a material change in treatment.
Begin with the specific question answered on this page: Single-dose intravaginal metronidazole vs single-dose oral secnidazole brand treatments. Do not use a comparison page to diagnose an infection or choose an antibiotic without a licensed clinician. Identify the medical purpose of the current prescription and check that the intended medicine, dosage form and route are clear enough for the dispensing pharmacist to verify.
Ask whether the authorized single-dose medicine is intravaginal Nuvessa or oral Solosec, then verify the applicator versus the packet. A pharmacy quote for one does not represent a clinically suitable alternative to the other. If route preference matters or a formulation is not usable, arrange a new prescribing conversation rather than attempting a home conversion.
No. Nuvessa contains metronidazole; Solosec contains secnidazole.
Their U.S. labeling describes single-administration regimens for BV, but the route and active drug differ.
No. It is oral secnidazole granules, not vaginal gel.
No. The SOLOSEC label directs patients to sprinkle the entire packet of granules on applesauce, yogurt or pudding and consume the mixture within 30 minutes without chewing the granules. It is not intended to dissolve in a liquid; water can be taken afterward if needed for swallowing.
Nuvessa vaginal gel is not the recommended treatment for trichomoniasis; diagnosis-specific oral therapy is needed.
FDA approved a therapeutically equivalent 1.3% vaginal gel referencing Nuvessa in 2024, but stock must be confirmed.
No. Route, ingredient and evidence matter more than a one-dose slogan.
An insurer may have coverage rules, but a change of drug or route requires clinician authorization.
Yes, both products require valid U.S. prescriptions.
Arrange clinical reassessment; do not administer a second dose on your own.